Novel cyclic and linear oligopeptides that bind to integrin β1 chain and either inhibit or costimulate T lymphocytes

International Immunopharmacology

Volumn 3, Issue 3, 2003, Pages 435-443

  Rao, Wei Hong ^a   Camp, Richard D R ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Costimulation; Inhibition; Peptides; T lymphocytes; 1 integrin

Indexed keywords

CYCLO(CYSTEINYLGLUTAMYLSERYLASPARAGINYLLYSYLPROLYLTRYPTOPHYLTYROSYLCYSTEINE ); CYCLO(CYSTEINYLISOLEUCYLLEUCYLTHREONYLASPARTYLMETHIONYLPROLYLHISTIDYLCYSTEI NE); CYCLO(CYSTEINYLLYSYLALANYLTHREONYLASPARAGINYLMETHIONYLHISTIDYLMETHIONYLCYSTEI NE); CYCLO(CYSTEINYLSERYLSERYLALANYLASPARAGINYLHISTIDYLGLUTAMINYLTHREONYLCYSTEIN E); ALANYLCYSTEINYLPROLYLTYROSYLLYSYLGLUTAMYLPROLINE; ANTIBODY; ASPARAGINYLTHREONYLSERYLSERYLGLUTAMINYLARGINYLPROLINE; BETA1 INTEGRIN; COLLAGEN TYPE 1; CYCLO(CYSTEINYLARGINYLALANYLTHREONYLPROLYLGLUTAMYLPROLYLGLYCYLCYSTEINE); CYCLO(CYSTEINYLPROLYLSERYLSERYLVALYLARGINYLHISTIDYLSERYLCYSTEINE); CYCLO(CYSTEINYLPROLYLTYROSYLLYSYLGLYCYLPROLYLSERYLGLUTAMYLCYSTEINE); CYCLO(CYSTEINYLSERYLLEUCYLARGINYLPROLYLLEUCYLGLUTAMYLISOLEUCYLCYSTEINE); CYCLOPEPTIDE; FIBRONECTIN; GLYCYLPROLYLVALYLASPARAGINYLPROLYLLEUCYLSERINE; METHIONYLTHREONYLALANYLPROLYLPROLYLARGINYLASPARAGINE; OLIGOPEPTIDE; PHENYLALANYLSERYLALANYLTYROSYLARGINYLISOLEUCYLGLYCINE; PHENYLALANYLTHREONYLARGINYLVALYLPROLYLALANYLASPARAGINE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING SITE; CELL INTERACTION; CONTROLLED STUDY; DISULFIDE BOND; DRUG PROTEIN BINDING; ELUTION; ENRICHMENT CULTURE; HUMAN; HUMAN CELL; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE ACTIVATION;

EID: 0037333911     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(03)00041-9     Document Type: Article

References (28)

1. Matsuyama T., Yamada A., Kay J., Yamada K.M., Akiyama S.K., Schlossman S.F.et al. Activation of CD4 cells by fibronectin and anti-CD3 antibody. J. Exp. Med. 170:1989;1133-1148.
2. + T cells by the interaction of VLA-4 and VLA-5 with fibronectin or VLA-6 with laminin. J. Immunol. 145:1990;59-67.
3. Davis L.S., Oppenheimer-Marks N., Bednarczyk J.L., McIntyre B.W., Lipsky P.E. Fibronectin promotes proliferation of naive and memory T cells by signaling through both the VLA-4 and VLA-5 integrin molecules. J. Immunol. 145:1990;785-793.
4. Rao W.H., Hales J.M., Camp R.D.R. Potent costimulation of effector T lymphocytes by human collagen type I. J. Immunol. 165:2000;4935-4940.
5. Hemler M.E., Jacobson J.G., Brenner M.B., Mann D., Strominger J.L. VLA-1: a T cell surface antigen which defines a novel late stage of human T cell activation. Eur. J. Immunol. 15:1985;502-508.
6. Hemler M.E., Jacobson J.G., Strominger J.L. Biochemical characterization of VLA-1 and VLA-2: cell surface heterodimers on activated T cells. J. Biol. Chem. 260:1985;15246-15252.
7. 1 recognize the same specific amino acid sequence, GFOGER, in native (triple-helical) collagens. J. Biol. Chem. 275:2000;35-40.
8. 1 integrin)-mediated cell adhesion. Discovery of compounds like cyclo(MePhe-Leu-Asp-Val-D-Arg-D-Arg) (ZD7349) compatible with depot formulation. J. Pept. Sci. 6:2000;398-412.
9. de Fougerolles A.R., Sprague A.G., Nickerson-Nutter C.L., Chi-Rosso G., Rennert P.D., Gardner H.et al. Regulation of inflammation by collagen-binding integrins α1β1 and α2β1 in models of hypersensitivity and arthritis. J. Clin. Invest. 105:2000;721-729.
10. Takada Y., Puzon W. Identification of a regulatory region of integrin β1 subunit using activating and inhibiting antibodies. J. Biol. Chem. 268:1993;17597-17601.
11. Luque A., Gómez M., Puzon W., Takada Y., Sánchez-Madrid F., Cabañas C. Active conformations of very late activation integrins detected by a group of antibodies (HUTS) specific for a novel regulatory region (355-425) of the common β1 chain. J. Biol. Chem. 271:1996;11067-11075.
12. Smith J.D., Cortes N.J., Evans G.S., Read R.C., Finn A. Induction of β2 integrin-dependent neutrophil adhesion to human alveolar epithelial cells by type 1 streptococcus pneumoniae and derived soluble factors. J. Infect. Dis. 177:1998;977-985.
13. Chisholm P.L., Williams C.A., Lobb R.R. Monoclonal antibodies to the integrin α-4 subunit inhibit the murine contact hypersensitivity response. Eur. J. Immunol. 23:1993;682-688.
14. Issekutz T.G. Dual inhibition of VLA-4 and LFA-1 maximally inhibits cutaneous delayed-type hypersensitivity-induced inflammation. Am. J. Pathol. 143:1993;1286-1293.
15. Issekutz A.C., Ayer L., Miyasaka M., Issekutz T.B. Treatment of established adjuvant arthritis in rats with monoclonal antibody to CD18 and very late activation antigen-4 integrins suppresses neutrophil and T-lymphocyte migration to the joints and improves clinical disease. Immunology. 88:1996;569-576.
16. 2)5CO), a novel, selective, cyclic peptide inhibitor of VLA-4-mediated cell adhesion. Br. J. Pharmacol. 126:1999;1751-1760.
17. Horrocks C., Duncan J.I., Sewell H.F., Ormerod A.D., Thomson A.W. Differential effects of cyclosporine A on Langerhans cells and regulatory T-cell populations in severe psoriasis: an immunohistochemical and flow cytometric analysis. J. Autoimmun. 3:1990;559-570.
18. Jones P.H., Watt F.M. Separation of human epidermal stem cells from transit amplifying cells on the basis of differences in integrin function and expression. Cell. 73:1993;713-724.
19. Carroll J.M., Romero M.R., Watt F.M. Suprabasal integrin expression in the epidermis of transgenic mice results in developmental defects and a phenotype resembling psoriasis. Cell. 83:1995;957-968.
20. Brakebusch C., Grose R., Quondamatteo F.F., Ramirez A., Jorcano J.L., Pirro A.et al. Skin and hair follicle integrity is crucially dependent on β1 integrin expression on keratinocytes. EMBO J. 19:2000;3990-4003.
21. Languino L.R., Gehlsen K.R., Wayner E., Carter W.G., Engvall E., Ruoslahti E. Endothelial cells use α2β1 integrin as a laminin receptor. J. Cell Biol. 109:1989;2455-2462.
22. 1 (VLA-2) is a principal receptor used by neutrophils for locomotion in extravascular tissue. Blood. 95:2000;1804-1809.
23. Smith C., Cerundolo V. Immunotherapy of melanoma. Immunology. 104:2001;1-7.
24. Pearson W.R., Lipman D.J. Improved tools for biological sequence comparison. Proc. Natl. Acad. Sci. 85:1988;2444-2448.
25. James R., Erler T., Kazenwadel J. Structure of the murine homeobox gene cdx-2. Expression in embryonic and adult intestinal epithelium. J. Biol. Chem. 269:1994;15229-15237.
26. Mallo G.V., Rechreche H., Frigerio J.M., Rocha D., Zweibaum A., Lacasa M.et al. Molecular cloning, sequencing and expression of the mRNA encoding human Cdx1 and Cdx2 homeobox. Down-regulation of Cdx1 and Cdx2 mRNA expression during colorectal carcinogenesis. Int. J. Cancer. 74:1997;35-44.
27. 1, from MG-63 and HT1080 cells, interacts with a cyclic RGD peptide. J. Biol. Chem. 267:1992;23159-23164.
28. Cardarelli P.M., Cobb R.R., Nowlin D.M., Scholz W., Gorcsan F., Moscinski M.et al. Cyclic RGD peptide inhibits α4β1 interaction with connecting segment 1 and vascular cell adhesion molecule. J. Biol. Chem. 269:1994;18668-18673.